The partners will enrol patients under the Syapse Learning Health Network to clinical trials sponsored by Amgen. The companies aim to launch these trials at community health sites.
Physicians and researchers under the Syapse Network will be able to access trial analytics, real-world evidence-based insights and collaborative research opportunities.
Amgen will also have access to trial data, which it can use to support development candidates in regulatory filings.
Syapse CEO Ken Tarkoff said: “Through this collaboration and the strategic relationships we’ve built with community health systems globally, we aim to develop evidence of clinical utility that can be used to bring molecularly targeted treatments to market more quickly and ensure more diverse groups of patients can access them.”
Amgen expects the alliance to facilitate decision-making tools. Its strategy, commercialisation and innovation senior vice-president Mike Nohaile said: “As cancer remains one of the leading causes of death around the world, emerging software and data analytic tools are creating exciting opportunities to more rapidly develop and deliver targeted treatment options to patients.
“Our collaboration with Syapse supports this effort by leveraging real-world evidence to accelerate bringing new oncology treatments to market and empowers healthcare providers with more robust insights and decision-making tools to improve patient care.”
Recently, Amgen reported financial results for the first quarter of this year. It recorded total revenues of $5.6bn, flat compared to the first quarter of last year. However, total product sales fell by 1%.